Technology ID
TAB-3425

TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS

E-Numbers
E-213-2015-0
Lead Inventor
Jacobson, Kenneth (NIDDK)
Co-Inventors
Kiselev, Evgeny (NIGMS)
Uliassi, Elisa (NIDDK)
Junker, Anna (NIDDK)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Pulmonology
Immunology
Endocrinology
Development Stages
Pre-Clinical (in vitro)
Research Products
Research Equipment
Lead IC
NIDDK
ICs
NIGMS
NIDDK
The technology describes the composition of small molecule compounds that are antagonists of the P2Y14 receptor. Also provided are methods of using the compounds, including a method of treating a disorder, such as inflammation, diabetes, insulin resistance, hyperglycemia, a lipid disorder, obesity, a condition associated with metabolic syndrome, and asthma, and a method of antagonizing P2Y14 receptor activity in a cell.
Commercial Applications
  • Development of P2Y14 receptor antagonist for treatment of disorders, such as:
  • Inflammation
  • diabetes
  • obesity
  • asthma
  • lipid disorder
  • metabolic syndromer

Request More Info

Licensing Contact:
Tong, Betty
tongb@niddk.nih.gov

Patents

  • US
    Provisional (PRV) 62/233,162
    Filed on 2015-09-25
  • Patent Cooperation Treaty
    (PCT) PCT/US16/053397
    Filed on 2016-09-23
  • US Patent 10,683,277
    Filed on 2018-03-23

Publications

Collaborations

  • Collaboration

Collaboration Description

  • The NIDDK is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS. For collaboration opportunities, please contact Kenneth A. Jacobson, Ph.D. at ,a href="mailto:kennethj@niddk.nih.gov">kennethj@niddk.nih.gov
Date Published